

## Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. *N Engl J Med* 2008;358:36-46.

**Supplement A: Treatment Exposure**

	<b>ECF n=250</b>	<b>ECX n=243</b>	<b>EOF n=236</b>	<b>EOX n=239</b>
<b>Total no. of cycles delivered</b>	1310	1400	1285	1295
<b>Median No cycles</b>	6	6	6	6
<b>p-value*</b>		0.021	0.323	0.426
<b>Fluoropyrimidine (% dose)</b>	90.5	88.4	88.3	88.1
<b>p-value*</b>		0.185	0.242	0.116
<b>Platinum dose (% dose)</b>	92.6	92.3	91.7	91.6
<b>p-value*</b>		0.836	0.261	0.163
<b>Epirubicin (% dose)</b>	92.6	89.2	93.0	91.9
<b>p-value*</b>		0.003	0.571	0.372
<b>% of patients with a delay</b>	58.8%	60.1%	47.9%	50.2%
<b>Mean days delayed per pat</b>	7.7	11.2	5.8	7.4
<b>p-value*</b>		0.121	0.01	0.072

\*Compared to ECF